Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03862651
Other study ID # MB11-2018
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2019
Est. completion date January 1, 2021

Study information

Verified date March 2019
Source Ospedale Santa Croce-Carle Cuneo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation. It seeks to determine if initiation of a prolonged cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and whether a cangrelor infusion before cardiac and non cardiac procedures is safe.


Description:

This will be a randomized, double-blind, placebo-controlled study enrolling patients with coronary stent, still on DAPT, undergoing cardiac and non cardiac surgery within 12 months from coronary stent implantation.

The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation. It seeks to determine if initiation of a prolonged cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and whether a cangrelor infusion before cardiac and non cardiac procedures is safe.

The primary efficacy objective of this study is to demonstrate that a cangrelor infusion will maintain levels of residual platelet reactivity (PRU < 208) as measured by Accriva VerifyNow® P2Y12 assay.

The main safety objective is to demonstrate that patients receiving cangrelor infusion before cardiac and non cardiac surgery have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 140
Est. completion date January 1, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Provide written informed consent before initiation of any study related procedures.

2. Be = 18 years of age.

3. Have received any dose of a P2Y12 inhibitor (clopidogrel, ticlopidine, prasugrel, or ticagrelor) at any dose within at least 48 hours prior to randomization.

4. Patients undergoing non deferrable cardiac or non cardiac surgery which requires discontinuation of P2Y12 inhibitor due to a significant bleeding risk.

Exclusion Criteria:

1. Confirmed of suspected pregnancy (if woman of child-bearing potential) or lactating females

2. Active bleeding with evident contraindications to DAPT

3. Patients requiring oral anticoagulant therapy

4. PCI within 1 month

5. Intracranial neoplasm or history of intracranial surgery

6. History of bleeding diathesis

7. Thrombocytopenia (platelet count of less than 100,000/µL)

8. Known International Normalized Ratio (INR) greater than 1.5 at screening.

9. Requirement for dialysis treatment (hemodialysis or peritoneal)

10. Estimated Glomeular filtration rate eGFR <30 ml/min

11. Administration of abciximab within 24 hours of randomization or administration of eptifibitide or tirofiban within 12 hours of randomization

12. Plans to continue oral anticoagulant or P2Y12 inhibitors or cangrelor in the pre-operative period

13. Refusal to receive blood transfusion

14. Receipt of fibrinolytic therapy in the 12 hours preceding randomization

15. Allergy, hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose

16. High likelihood of being unavailable for follow-up

17. Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization

18. Any disease or condition which, in the judgment of the investigator, would place the patient at undue risk by being enrolled in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cangrelor
Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ospedale Santa Croce-Carle Cuneo

References & Publications (6)

Albaladejo P, Marret E, Samama CM, Collet JP, Abhay K, Loutrel O, Charbonneau H, Jaber S, Thoret S, Bosson JL, Piriou V. Non-cardiac surgery in patients with coronary stents: the RECO study. Heart. 2011 Oct;97(19):1566-72. doi: 10.1136/hrt.2011.224519. Epub 2011 Jul 26. — View Citation

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25. Review. Erratum in: Circulation. 2017 Mar 7;135(10 ):e646. Circulation. 2017 Sep 5;136(10 ):e196. — View Citation

Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007 Jun 5;49(22):2145-50. Epub 2007 May 23. Review. — View Citation

Moschovitis A, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2006. EuroIntervention. 2010 Jun;6(2):189-94. doi: 10.4244/. — View Citation

Rossini R, Musumeci G, Capodanno D, Lettieri C, Limbruno U, Tarantini G, Russo N, Calabria P, Romano M, Inashvili A, Sirbu V, Guagliumi G, Valsecchi O, Senni M, Gavazzi A, Angiolillo DJ. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost. 2015 Feb;113(2):272-82. doi: 10.1160/TH14-05-0436. Epub 2014 Oct 2. — View Citation

Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, Hoeks SE, Poldermans D. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007 Jan 2;49(1):122-4. Epub 2006 Dec 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary LEVEL OF RESIDUAL PLATELET REACTIVITY Accriva VerifyNow P2Y12 assay 1-2 hours
Secondary ischemic and hemorrhagic endpoints Bleeding Academic Research Consortium (BARC) grade > 3 30 days
See also
  Status Clinical Trial Phase
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Recruiting NCT04796714 - AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE Phase 4
Completed NCT02711410 - The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients N/A
Completed NCT05278637 - GM03 - Platelet RNA Signatures of Aspirin Early Phase 1
Recruiting NCT03288441 - Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Recruiting NCT05306951 - Correct Timing of Head Imaging in Trauma
Recruiting NCT05732701 - Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions N/A
Recruiting NCT05702463 - Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II Phase 1
Completed NCT01354808 - ACCEL-LOADING-ACS Study Phase 4
Completed NCT00799396 - Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Phase 4
Completed NCT00325390 - Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Phase 3
Completed NCT04999293 - Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
Completed NCT04328883 - Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin Phase 1
Completed NCT02808767 - Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction Phase 4
Completed NCT00769938 - WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) Phase 4
Completed NCT03599284 - The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel Phase 2
Completed NCT03785509 - The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
Unknown status NCT01103843 - Plavix, Prasugrel and Drug Eluting Stents Pilot Trial N/A
Active, not recruiting NCT03462498 - ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS Phase 4